# Natera, Inc. (NTRA) Stock Analysis: Riding a Wave of 37.7% Revenue Growth and Strong Buy Ratings

- Link: https://www.directorstalkinterviews.com/natera-inc-ntra-stock-analysis-riding-a-wave-of-37-7-revenue-growth-and-strong-buy-ratings/4121267850
- Published: 2026-10-26T11:07:32+00:00
- Author: Madison Wilson

Natera, Inc. (NTRA), a prominent player in the healthcare sector specializing in
diagnostics and research, has been capturing investor attention with its significant
revenue growth and robust market position. Headquartered in Austin, Texas, Natera
has carved a niche in molecular testing services, offering a diverse portfolio that
includes cutting-edge cancer diagnostics and prenatal screening tests.

At a current price of $403.95, Natera’s stock has seen a modest price change of 
0.01%, reflecting a stable market presence. The stock’s 52-week range of $182.65
to $425.64 suggests a period of substantial growth, positioning Natera as a formidable
force in its industry. Despite a challenging economic environment, the company boasts
a market capitalization of $58.23 billion, underscoring its scale and influence 
in the diagnostics field.

One of the standout figures for Natera is its impressive revenue growth rate of 
37.70%. This metric highlights the company’s ability to expand its market share 
and drive financial performance, even as it navigates the complexities of its industry.
However, the company’s financials also reveal areas that require attention, such
as a negative EPS of -1.35 and a return on equity of -12.54%. These figures indicate
the company’s current focus on reinvestment and growth over immediate profitability.

Investors should note the absence of traditional valuation metrics, such as the 
P/E ratio and PEG ratio, which are not applicable due to the company’s current earnings
situation. Instead, Natera’s valuation is largely driven by growth potential and
market sentiment. The forward P/E ratio stands at an eye-catching -2,271.42, which
reflects the company’s aggressive growth strategy and investment in future capabilities.

Analysts are largely optimistic about Natera’s prospects, with 21 buy ratings and
only 2 hold ratings, and no sell ratings. This bullish sentiment is supported by
the target price range of $280.00 to $500.00, with an average target of $411.39.
Such a target suggests a potential upside of 1.84%, indicating moderate room for
growth in the near term. This is further corroborated by the stock’s technical indicators,
with a 50-day moving average of $366.97 and a 200-day moving average of $261.62,
pointing to an upward trend in stock price.

Natera’s innovative offerings, including the Signatera and Panorama tests, position
the company at the forefront of personalized medicine and non-invasive diagnostics.
The company’s strategic partnership with BGI Genomics Co., Ltd. for the development
of genetic testing assays further enhances its competitive edge and global reach.

While Natera does not currently offer a dividend yield, its substantial free cash
flow of $104.03 million supports reinvestment into research and development, a critical
factor for long-term growth in the healthcare sector. This reinvestment is vital
not only for maintaining technological leadership but also for expanding its product
offerings and entering new markets.

Investors considering Natera should weigh the company’s robust growth potential 
against the risks inherent in its current financial posture. The diagnostics and
research industry is rapidly evolving, and Natera’s focus on innovation and strategic
partnerships positions it well for future success, making it a compelling option
for growth-oriented investors.

Share on: